0-72. Rivizor® versus aminoglutethimide (AG) in the second-line endocrine treatment of postmenopausal patients with advanced breast cancer (ABC) following tamoxifen failure

✍ Scribed by S.J. Houston

• Book ID: 114317078
• Publisher: Elsevier Science
• Year: 1997
• Tongue: English
• Weight: 300 KB
• Volume: 6
• Category: Article
• ISSN: 0960-9776
• DOI: 10.1016/s0960-9776(97)90653-6